Postdoctoral Opportunities in Tumor Microenvironment/Immunology

Are you looking for postdoctoral opportunities? We may be looking for you! OHSU, home of the Knight Cancer Network, is located in beautiful Portland, Oregon. Contact our labs below to find out more. 

Julia Maxson, Ph.D.

Julia Maxson, Ph.D.: We study how genomic changes manifest at the cellular level to promote cancer formation and progression. We focus on understanding how genetic alterations cooperate to drive leukemia to develop therapeutic strategies.
Maxson Lab

Lara Davis, M.D.

Lara E. Davis, M.D.: We focus on translational sarcoma research. Current projects include targeting the osteosarcoma immune microenvironment through analysis of tumor biopsies and in vivo modelling; identification and characterization of unrecognized kinase fusions in complex karyotype sarcomas; and optimizing CDK4 inhibition as a method to increase sarcoma sensitivity to chemotherapy. All projects incorporate human tumor specimens and we frequently conduct correlative.
Davis Lab

Alexey Danilov, M.D., Ph.D.

Alexey Danilov, M.D., Ph.D.: We conduct highly translational research leading to innovative clinical trials. Interests include novel targets within the ubiquitin-proteasome pathway; mechanism of action and resistance to transcriptional CDKs. The project will focus on cancer cell signaling and investigate novel molecular targets in B-cell malignancies, and will match the candidate’s interests and experience.

Gordon Mills, M.D., Ph.D.

Gordon Mills, M.D., Ph.D.: Join a highly productive dynamic translational research effort, characterizing mechanisms of drug sensitivity and resistance in human tumors. Access to human tissues as well as a broad array of wet bench and bioinformatics tools provides a rich environment for fellows to explore. Mills Lab

Sudarshan Anand, Ph.D.

Sud Anand, Ph.D.: We are broadly interested in identifying and characterizing non-coding RNAs in the host cells that impact tumor progression. We welcome candidates that can lead efforts to understand functions of non-coding RNAs in immune cells in the tumor microenvironment.
Anand Lab

Amy Moran, Ph.D.

Amy Moran, Ph.D.: Work in a translational cancer immunotherapy lab evaluating the cross talk between sex steroids and immune cell function. Current projects include the role of the microbiome in modulating immuno-therapy responses and immune cell function (in a clinical trial and mouse model) and novel mechanisms of action of non-conventional inhibitors of T & NK cell function.
Moran Lab

Ferdinando Pucci, Ph.D.

Ferdinando Pucci, Ph.D.: We focus on understanding humoral immune responses to malignant transformation and how they affect cell-mediated immunity, with the goal of developing next generation cancer vaccines. We couple genetic engineering and in vivo imaging of sentinel lymph nodes to study antigen-specific immune reactions to tumor-derived extracellular vesicles.
Pucci Lab

Rosalie Sears, Ph.D.

Rosalie Sears, Ph.D.: Work on pancreatic cancer focused on tumor heterogeneity, lineage plasticity, epigenetic regulation and mechanisms of therapeutic resistance. We use sophisticated omic and image analysis of patient tumors, patient-derived models using 3D bioprinting and genetic mouse models. Candidates must have a Ph.D. and/or M.D. degree and extensive training in the areas of cancer biology, molecular biology, biochemistry, cell biology, and mouse modeling.
Sears Lab

Lisa Coussens, Ph.D.

Lisa M Coussens, Ph.D.: We are broadly interested in understanding signals controlling innate and adaptive leukocyte responses and activities in solid tumors. Multiple projects are available to examine myeloid - T cell cross talk and mechanisms regulated by complement proteins as mediators of tumor progression and anti-tumor immunity using both mouse models of human cancer and clinical specimens.
Coussens Lab

Joshua Walker, M.D., Ph.D.

Josh Walker, M.D., Ph.D.: Our research focuses on understanding the intrinsic and microenvironmental factors that regulate T cell effector dysfunction in cancer, extending from the differential effects of antigen presentation and priming on T cell effector fate to the effects of novel combinations of chemotherapy, radiotherapy, and immunotherapy on T cell effector function in advanced cancer. Our work utilizes both preclinical models with defined tumor antigens where the timing and strength of T cell stimulation can be manipulated as well as a range of clinical samples in order to explore this biology.
Walker Lab